| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/30/2002 | EP1175246A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| 01/30/2002 | EP1175235A1 Modified protein matrices |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175222A2 Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections |
| 01/30/2002 | EP1175221A2 Lactic acid bacteria with anxiolytic properties and uses thereof |
| 01/30/2002 | EP1175215A2 Use of osanetant in the production of medicaments used to treat mood disorders |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1175211A2 Anticonvulsant derivatives useful in treating cocaine dependency |
| 01/30/2002 | EP1175208A1 Composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative or an extract of a plant of genus angelicae containing same |
| 01/30/2002 | EP1021442B1 8-azabicyclo 3.2.1] octane-3-methanamine derivatives as ligands of d2 and d3 dopamine and 5ht1a and 5ht2 serotonin receptors |
| 01/30/2002 | EP0991409B1 Controlled release pharmaceutical compositions containing tiagabine |
| 01/30/2002 | EP0956009B1 Treatment of neurodegenerative conditions with nimesulide |
| 01/30/2002 | EP0904284B1 6-substituted amino-4-oxa-1-azabicyclo[3.2.0]heptan-7-one derivatives as cysteine protease inhibitors |
| 01/30/2002 | CN1333767A Aromatic heterocyclic compounds as antiinflammatory agent |
| 01/30/2002 | CN1333764A Benzofuran derivatives, process for the preparation of the same and uses thereof |
| 01/30/2002 | CN1333754A Benzoheterocycles and their use as MEK inhibitors |
| 01/30/2002 | CN1333691A Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| 01/30/2002 | CN1333690A Method for producing medicaments from plant extracts, in solid form of administration |
| 01/30/2002 | CN1333685A Utilisation of I compound for the prophylaxis and therapy of cerebral ischaemia |
| 01/30/2002 | CN1333684A Use of 5HT3 receptor antagouists for the treatment of chronic fatigue syndrome |
| 01/30/2002 | CN1333339A Polytype gene of MXA protein and application thereof |
| 01/30/2002 | CN1333042A Lxeris debilis extract preparation and application thereof |
| 01/30/2002 | CN1078477C Smoking-giving up tea and preparation |
| 01/30/2002 | CN1078469C Material for adjusting function of biology |
| 01/30/2002 | CN1078467C Application of sinomenine in preparing analgesic |
| 01/30/2002 | CN1078460C Program-controlled skin permeable plaster |
| 01/29/2002 | US6342604 Treating schizophrenia, depression, neuroses and psychoses which respond to dopamine d3 ligands |
| 01/29/2002 | US6342596 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/29/2002 | US6342581 Genetic engineering and expression of polynucleotides and polypeptides; vectors, cells, antibodies for diagnosis and disease treatment |
| 01/29/2002 | US6342533 Antidepressants udes for bipolar and attention deficit disorders, hyperactivity, parkinson's disease, epilepsy, eating disorders |
| 01/29/2002 | US6342531 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 01/29/2002 | US6342523 3,4,5-trisubstituted aryl nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation |
| 01/29/2002 | US6342521 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 01/29/2002 | US6342511 Racemic, enantiomorphs and diasteriomorphs |
| 01/29/2002 | US6342510 Antiinflammatory agents and enzyme inhibitors |
| 01/29/2002 | US6342498 Arylpiperazines as serotonin reuptake inhibitors and 5-HT1Dα antagonists |
| 01/29/2002 | US6342496 Bupropion metabolites and methods of use |
| 01/29/2002 | US6342488 Treating psychosis without side effects in humans |
| 01/29/2002 | US6342476 Treating multiple sclerosis by administering a copolymer reacted with hydrobromic acid |
| 01/29/2002 | US6342383 Reverse transcriptase activity; endogenous retroviruses |
| 01/29/2002 | US6342351 Methods and compositions for diagnosing and treating chromosome-18p related disorders |
| 01/29/2002 | US6342251 Compositions for nasal administration |
| 01/29/2002 | CA1341335C 9-amino-1, 4 ethano-1, 2, 3, 4-tetrahydroacridine and related compounds, intermediates and a process for the preparation thereof an their use as medicaments |
| 01/27/2002 | CA2353768A1 Use of growth hormone secretagogues for improvement of functional health status |
| 01/24/2002 | WO2002006492A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 01/24/2002 | WO2002006483A1 Novel physiologically active peptide and use thereof |
| 01/24/2002 | WO2002006466A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/24/2002 | WO2002006453A2 Regulation of human desc1-like serine protease |
| 01/24/2002 | WO2002006316A2 Alpha-msh related compounds and methods of use |
| 01/24/2002 | WO2002006306A2 SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY |
| 01/24/2002 | WO2002006293A1 Matrix metalloproteinase inhibitors |
| 01/24/2002 | WO2002006288A1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 01/24/2002 | WO2002006286A2 IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| 01/24/2002 | WO2002006285A1 Imidazolophthalazine derivatives as ligands for gabaa receptors |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006275A1 Novel processes for the preparation of 4-phenylpiperidine derivatives |
| 01/24/2002 | WO2002006272A1 Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof |
| 01/24/2002 | WO2002006271A1 Pyrimidine derivatives |
| 01/24/2002 | WO2002006270A1 Novel 6-heteroarylphenanthridines |
| 01/24/2002 | WO2002006254A1 Tetrazole derivatives |
| 01/24/2002 | WO2002006245A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 01/24/2002 | WO2002006242A2 5-substituted 2-aryl-4-pyrimidinones |
| 01/24/2002 | WO2002006240A1 Substituted 4,9-dihydrocyclopenta[imn] phenanthridine-5-ones, derivatives thereof and their uses |
| 01/24/2002 | WO2002006236A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 01/24/2002 | WO2002006232A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006231A1 Serotonin reuptake inhibitors |
| 01/24/2002 | WO2002006224A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | WO2002006223A1 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 01/24/2002 | WO2002006222A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 01/24/2002 | WO2002006215A1 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivates |
| 01/24/2002 | WO2002006213A2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 01/24/2002 | WO2002005859A2 Radiotherapy |
| 01/24/2002 | WO2002005851A2 Enhancement of the action of central and peripheral nervous system agents |
| 01/24/2002 | WO2002005849A2 Transportation of nucleic acid substances |
| 01/24/2002 | WO2002005848A2 Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| 01/24/2002 | WO2002005822A2 Compositions containing therapeutically active components having enhanced solubility |
| 01/24/2002 | WO2002005817A1 Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence |
| 01/24/2002 | WO2002005813A2 Method for preventing and/or decreasing amyloid production with polycyclic compounds |
| 01/24/2002 | WO2002005801A2 Compositions containing diacyltartaric salts of (e)-metanicotine |
| 01/24/2002 | WO2002005799A2 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| 01/24/2002 | WO2002005798A2 Pharmaceutical compositions for treating neurological disorders |
| 01/24/2002 | WO2002005797A2 Use of dopamine d2/d3 receptor agonists to treat fibromyalgia |
| 01/24/2002 | WO2002005795A2 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2002005784A1 A medicinal aerosol formulation |
| 01/24/2002 | WO2002005782A2 Stable salts of o-acetylsalicyclic with basic amino acids |
| 01/24/2002 | WO2002005749A2 Crf2 ligands in combination therapy |
| 01/24/2002 | WO2001058875A3 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives |
| 01/24/2002 | WO2001056992A3 Dibenzo (b,f) azepine intermediates |
| 01/24/2002 | WO2001052878A3 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 01/24/2002 | WO2001047506A3 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001038305A3 Novel il-8 receptor antagonists |
| 01/24/2002 | WO2001036005A3 Targeted delivery of therapeutic and diagnostic moieties |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001032910A3 27 human secreted proteins |
| 01/24/2002 | WO2001027107A3 Heterocyclic sodium/proton exchange inhibitors and method |
| 01/24/2002 | WO2001023387A3 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| 01/24/2002 | WO2001023385A3 Novel tropane analogs |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |